Skip to main content

Advertisement

SpringerLink
Log in

Advances in the Evaluation and Management of Minimal Hepatic Encephalopathy

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Minimal hepatic encephalopathy (MHE) is a neurocognitive disorder that affects up to 80% of cirrhotic patients. Similar to overt hepatic encephalopathy, ammonia and oxidative stress play key roles in the pathogenesis of MHE. However, MHE is characterized by subtle deficits and psychomotor abnormalities that can only be elicited by specialized psychometric tests. Although no gold standard exists for the diagnosis, MHE remains an important entity for clinicians to recognize because of its negative impact on a patient’s health-related quality of life and association with driving impairment and vehicle accidents. MHE has also been associated with an increased rate in the development of overt hepatic encephalopathy and increased mortality; therefore, identification and treatment should not be delayed. Treatment to date has been focused on reducing serum ammonia levels with agents such as lactulose, probiotics, and synbiotics. MHE is a real and growing problem that is epidemic in cirrhosis, and increasing awareness of this condition is necessary for adequate management of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Bajaj JS, Wade JB, Sanyal AJ: Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology 2009, 50:2014–2021. This article provides a detailed analysis of the available testing strategies for MHE and the need to treat this as a spectrum of disease.

    Article  PubMed  Google Scholar 

  2. Ferenci P, Lockwood A, Mullen K, et al.: Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35:716–721.

    Article  PubMed  Google Scholar 

  3. Mullen KD: Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Aliment Pharmacol Ther 2007, 25(Suppl 1):11–16.

    Article  PubMed  Google Scholar 

  4. • Randolph C, Hilsabeck R, Kato A, et al.: Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009, 29:629–635. This review provides a consensus for neuropsychological assessment in patients at risk for MHE.

    Article  PubMed  Google Scholar 

  5. Dhiman RK, Saraswat VA, Sharma BK, et al.; Indian National Association for Study of the Liver: Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol 2010, 25:1029–1041.

    Article  PubMed  Google Scholar 

  6. Sharma P: Minimal hepatic encephalopathy. J Assoc Physicians India 2009, 57: 760–763.

    PubMed  Google Scholar 

  7. Dhiman RK, Chawla YK: Minimal hepatic encephalopathy. Indian J Gastroenterol 2009, 28:5–16.

    Article  PubMed  Google Scholar 

  8. Sharma P, Sharma BC: Predictors of minimal hepatic encephalopathy in patients with cirrhosis. Saudi J Gastroenterol 2010, 16:181–187.

    Article  PubMed  Google Scholar 

  9. Bajaj JS: Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008, 14:3609–3615.

    Article  PubMed  Google Scholar 

  10. Sharma P, Sharma BC, Puri V, Sarin SK: Natural history of minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction. Am J Gastroenterol 2009, 104:885–890.

    Article  PubMed  Google Scholar 

  11. Groeneweg M, Quero JC, De Bruijn I, et al.: Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998, 28:45–49.

    Article  CAS  PubMed  Google Scholar 

  12. Groeneweg M, Moerland W, Quero JC, et al.: Screening of subclinical hepatic encephalopathy. J Hepatol 2000, 32:748–753.

    Article  CAS  PubMed  Google Scholar 

  13. Zhou YQ, Chen SY, Jiang LD, et al.: Development and evaluation of the quality of life instrument in chronic liver disease patients with minimal hepatic encephalopathy. J Gastroenterol Hepatol 2009, 24:408–415.

    Article  PubMed  Google Scholar 

  14. Kim Y, Park G, Lee M, Lee JH: Impairment of driving ability and neuropsychological function in patients with MHE disease. Cyberpsychol Behav 2009, 12:433–436.

    Article  PubMed  Google Scholar 

  15. Wein C, Koch H, Popp B, et al.: Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004, 39:739–745.

    Article  PubMed  Google Scholar 

  16. Bajaj JS, Hafeezullah M, Zadvornova Y, et al.: The effect of fatigue on driving skills in patients with hepatic encephalopathy. Am J Gastroenterol 2009, 104:898–905.

    Article  PubMed  Google Scholar 

  17. •• Bajaj JS, Saeian K, Schubert CM, et al.: Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009, 50:1175–1183. This article provides actual translation from driving tests to retrospective and prospective driving offenses in MHE patients.

    Article  PubMed  Google Scholar 

  18. Kircheis G, Knoche A, Hilger N, et al.: Hepatic encephalopathy and fitness to drive. Gastroenterology 2009, 137:1706–1715.

    Article  PubMed  Google Scholar 

  19. Mullen KD: Pathogenesis, clinical manifestation, and diagnosis of hepatic encephalopathy. Semin Liver Dis 2007, 27:3–9.

    Article  Google Scholar 

  20. •• Seyan AS, Hughes RD, Shawcross DL: Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol 2010, 16:3347–3357. This article provides a comprehensive review of the pathophysiologic mechanisms of ammonia and oxidative stress in the development of MHE.

    Article  PubMed  Google Scholar 

  21. Mullen KD, Ferenci P, Bass NM, et al.: An algorithm for the management of hepatic encephalopathy. Semin Liver Dis 2007, 27:32–48.

    Article  Google Scholar 

  22. Gorg B, Qvartskhava N, Bidmon HJ, et al.: Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy. Hepatology 2010, 52:256–265.

    PubMed  Google Scholar 

  23. Shawcross DL, Davies NA, Williams R, Jalan R: System inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004, 40:247–254.

    Article  CAS  PubMed  Google Scholar 

  24. Shawcross D, Jalan R: The pathophysiologic basis of hepatic encephalopathy: central role of ammonia and inflammation. Cell Mol Life Sci 2005, 62:2295–2304.

    Article  CAS  PubMed  Google Scholar 

  25. Shawcross DL, Wright G, Olde Damink SW, Jalan R: Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 2007, 22:125–138.

    Article  CAS  PubMed  Google Scholar 

  26. Montoliu C, Piedrafita B, Serra MA, et al.: IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. J Clin Gastroenterol 2009, 43:272–279.

    Article  CAS  PubMed  Google Scholar 

  27. Liu Q, Duan ZP, Ha DK, et al.: Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004, 39:1441–1449.

    Article  PubMed  Google Scholar 

  28. Gupta A, Dhiman RK, Kumari S, et al.: Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010 (Epub ahead of print).

  29. • Jimenez B, Montoliu C, Macintyre DA, et al.: The serum metabolic signature of minimal hepatic encephalopathy by H-nuclear magnetic resonance. J Proteome Res 2010 (Epub ahead of print). The authors provide a metabolomic analysis of serum, which offers new insight into the disease process.

  30. •• Romero-Gómez M, Jover M, Del Campo JA, et al.: Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern Med 2010, 153:281–288. Genetic single-nucleotide polymorphism analysis in patients with cirrhosis that predicts overt HE.

    PubMed  Google Scholar 

  31. Bajaj JS, Hafeezullah M, Franco J, et al.: Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008, 135:1591–1600.

    Article  PubMed  Google Scholar 

  32. Stewart CA, Enders FT, Schneider N, et al.: Development of a three-factor neuropsychological approach for detecting minimal hepatic encephalopathy. Liver Int 2010, 30:841–849.

    Article  PubMed  Google Scholar 

  33. Sorrell JH, Zolnikov BJ, Sharma A, Jinnai I: Cognitive impairment in people diagnosed with end-stage liver disease evaluated for liver transplantation. Psychiatry Clin Neurosci 2006, 60:174–181.

    Article  PubMed  Google Scholar 

  34. Amodio P, Campagna F, Olianas S, et al.: Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. J Hepatol 2008, 49:346–353.

    Article  PubMed  Google Scholar 

  35. Sharma P, Sharma BC, Puri V, Sarin SK: Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol 2007, 47:67–73.

    Article  CAS  PubMed  Google Scholar 

  36. Sharma P, Sharma BC, Sarin SK: Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis. Hepatobiliary Pancreat Dis Int 2010, 9:27–32.

    CAS  PubMed  Google Scholar 

  37. Romero-Gomez M, Cordoba J, Jover R, et al.: Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007, 45:879–885.

    Article  PubMed  Google Scholar 

  38. Kircheis G, Wettstein M, Timmermann L, et al.: Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002, 35:357–366.

    Article  PubMed  Google Scholar 

  39. •• Dhiman RK, Kurmi R, Thumburu KK, et al.: Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci 2010, 55:2381–2390. This article shows that abnormal psychometric testing can adversely affect survival in patients with cirrhosis.

    Article  PubMed  Google Scholar 

  40. Amodio P, Ridola L, Schiff S, et al.: Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology 2010, 139:510–518.

    Article  PubMed  Google Scholar 

  41. Butz M, Timmermann L, Braun M, et al.: Motor impairment in liver cirrhosis without and with minimal hepatic encephalopathy. Acta Neurol Scand 2010, 122:27–35.

    Article  CAS  PubMed  Google Scholar 

  42. Singhal A, Nagarajan R, Hinkin CH, et al.: Two-dimensional MR spectroscopy of minimal hepatic encephalopathy and neuropsychological correlates in vivo. J Magn Reson Imaging 2010, 32:35–43.

    Article  PubMed  Google Scholar 

  43. Ortiz M, Jacas C, Cordoba J: Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol 2005, 42: S45–S53.

    Article  PubMed  Google Scholar 

  44. Tan HH, Lee GH, Thia KT, et al.: Minimal hepatic encephalopathy runs a fluctuating course: results from a three-year prospective cohort follow-up study. Singapore Med J 2009, 50:255–260.

    CAS  PubMed  Google Scholar 

  45. Hartmann IJC, Groeneweg M, Quero JC, et al.: The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000, 95:2029–2034.

    Article  CAS  PubMed  Google Scholar 

  46. Holecek M: Three targets of branched-chain amino acid supplementation in the treatment of liver disease. Nutrition 2010, 26:482–490.

    Article  CAS  PubMed  Google Scholar 

  47. Abdo-Francis J, Perez-Hernandez J, Hinojosa-Ruiz A, Hernandez-Vasquez J: Use of L-ornithine L-aspartate (LOLA) reduces time of hospital stay in patients with hepatic encephalopathy [in Spanish]. Rev Gastroenterol Mex 2010, 75:135–141.

    PubMed  Google Scholar 

  48. Schmid M, Peck-Radosavljevic M, Konig F, et al.: A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis. Liver Int 2010, 30:574–582.

    Article  CAS  PubMed  Google Scholar 

  49. Bajaj JS, Saeian K, Christensen KM, et al.: Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008, 103:1707–1715.

    Article  PubMed  Google Scholar 

  50. •• Bass NM, Mullen KD, Sanyal A, et al.: Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010 25, 362:1071–1081. Multicenter, randomized, placebo-controlled trial of rifaximin in patients with overt HE in which rifaximin reduced the recurrent episodes and hospitalizations for overt HE.

    Article  Google Scholar 

  51. Bajaj JS: Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010, 31:537–547.

    Article  CAS  PubMed  Google Scholar 

  52. McGuire BM, Zupanets IA, Lowe ME, et al.: Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 2010, 51:2077–2085.

    CAS  PubMed  Google Scholar 

  53. Prasad S, Dhiman RK, Duseja A, et al.: Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007, 45:549–559.

    Article  PubMed  Google Scholar 

  54. Sidhu S, Goyal O, Mishra BP, et al.: Rifaximin improves cognitive functions and health-related quality of life in patients with minimal hepatic encephalopathy: a prospective, randomized, double-blind, placebo-controlled trial (the RIME Trial) [abstract]. Gastroenterology 2010, 139:e18–e19.

    Article  Google Scholar 

  55. •• Bajaj JS, Heuman DM, Wade JB, et al.: Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2010. doi:10.1053/j.gastro.2010.08.061. This article describes a randomized, controlled trial showing rifaximin improved the driving capabilities of patients with MHE.

Download references

Disclosure

Conflicts of interest: J. Montgomery—none. J. Bajaj—fees for consultancy and travel expense reimbursement, and grants to Dr. Bajaj’s institution, from Salix and Ocera.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, 1201 Broad Rock Boulevard, Richmond, VA, 23249, USA

    Jennifer Y. Montgomery & Jasmohan S. Bajaj

Authors
  1. Jennifer Y. Montgomery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jasmohan S. Bajaj
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jasmohan S. Bajaj.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montgomery, J.Y., Bajaj, J.S. Advances in the Evaluation and Management of Minimal Hepatic Encephalopathy. Curr Gastroenterol Rep 13, 26–33 (2011). https://doi.org/10.1007/s11894-010-0150-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-010-0150-z

Keywords

Search

Navigation